Roche’s Announcement Regarding Sefaxersen (Announcement of Interim Analysis Results from the Phase III IMAGINATION Study)

TOKYO, September 24, 2026 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued a media release on September 23, regarding positive results from the interim analysis of the global Phase III IMAGINATION study evaluating sefaxersen in IgA nephropathy.

The detailed data will be presented at an upcoming medical meeting.

Please refer to the link below for details of Roche’s media release:

Positive interim data shows Roche’s sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN)

https://www.roche.com/media/releases/med-cor-2026-09-23b